Posted inNephrology news
Selective TRPC6 Inhibition Emerges as a Novel Therapeutic Paradigm for Focal Segmental Glomerulosclerosis
A Phase 2 trial of BI 764198, a selective TRPC6 inhibitor, demonstrates significant proteinuria reduction in patients with focal segmental glomerulosclerosis. This study provides the first clinical evidence for podocyte-targeted therapy, marking a potential shift in the management of progressive proteinuric kidney diseases.
